Welcome to our dedicated page for Avantor news (Ticker: AVTR), a resource for investors and traders seeking the latest updates and insights on Avantor stock.
Avantor, Inc. reports developments as a life science tools company supplying mission-critical products and services to life sciences and advanced technology customers through its VWR Distribution & Services and Bioscience & Medtech Products businesses. Recurring updates cover earnings, cash flow, leverage, guidance, segment performance and the company’s Revival transformation program, including VWR brand activity, manufacturing and supply-chain improvements and e-commerce upgrades.
Company news also covers portfolio and infrastructure actions such as Masterflex fluid handling systems, single-use assemblies, peristaltic pumps, J.T. Baker high-purity process chemicals, and expanded microbial and stability testing capabilities for regulated biopharma manufacturing. Governance and management updates include finance leadership changes and appointments tied to bioscience, medtech products and enterprise transformation.
Avantor, Inc. (NYSE: AVTR) has declared a quarterly cash dividend of $0.78 per share for its 6.250% Series A Mandatory Convertible Preferred Stock, reflecting a rate of 1.560%. The dividend will be payable on August 15, 2020, to holders of record as of August 1, 2020. This announcement underscores Avantor's commitment to return value to its shareholders.
Avantor has priced a private offering totaling $1.550 billion of 4.625% Senior Notes and €400 million of 3.875% Senior Notes, both maturing on July 15, 2028. The dollar-denominated notes were upsized from an initial $1.0 billion. The proceeds will be used to redeem all 9.000% Senior Notes due 2025. The offering is set to close on July 17, 2020.
Avantor (NYSE: AVTR) announced preliminary unaudited revenue estimates for Q2 2020, projecting earnings between $1.48 billion and $1.49 billion, down from $1.53 billion in Q2 2019, indicating a 2% to 3% organic revenue decline. The decline was primarily attributed to COVID-19 impacts in Education, Healthcare, and Advanced Technologies markets, though Biopharma remains strong. Concurrently, Avantor plans to increase its revolving credit facility to $515 million and extend its maturity to July 2025.
Avantor, a global leader in mission-critical products for life sciences, has announced a private offering of dollar and euro-denominated senior notes through its subsidiary, Avantor Funding. The offering aims to raise funds to redeem part of its 9.000% Senior Notes due 2025, along with covering related fees and expenses. The transaction will be conducted under exemptions from registration requirements in the U.S. The notes have not been registered and cannot be sold in the U.S. without proper registration.
Avantor (NYSE: AVTR) has announced the expansion of its Bridgewater, N.J. innovation center, nearly doubling laboratory and support space. This development aims to enhance R&D support for custom product and bioprocess development, including cell and gene therapy reagent manufacturing. The expansion aligns with the biopharma industry's focus on improving bioprocessing efficiency and complying with global regulatory standards. The site will also help minimize contamination risks in therapeutic product manufacturing.
Avantor, Inc. (NYSE: AVTR) announced its debut on the Fortune 500 list, ranking 484 based on revenue. Following its acquisition of VWR, Avantor has adapted its business model to meet demands in biopharma, healthcare, and applied technology. The company supports vaccine development amid COVID-19, serving over 225,000 customer locations globally. Key highlights include serving 10 of the top 10 medical device firms and having products specified in over 80% of the leading biologic drugs. Nearly half of its revenues come from biopharma, improving workflow in drug development.